Where the numbers come from
Sources
Primary sources for prices, regulatory facts, and clinical claims — with the priority order we apply when they conflict.
Pricing
Priority order: (1) the provider's own pricing/checkout pages, capture-dated (each record's source_url, archived where possible); (2) direct provider statements, labeled 'stated, not page-verified'; (3) credible third-party coverage, labeled and queued for recapture. Brand pricing: LillyDirect/Lilly pricing pages and announcements, NovoCare/Novo Nordisk pricing pages and offers, TrumpRx listings — refreshed 2026-08-09.
Regulatory
FDA drug-shortage database determinations and compounding guidance (tirzepatide resolution reaffirmed December 2024; semaglutide February 2025; 503A/503B enforcement dates; the April 2026 proposed 503B bulks-list rule); FDA warning letters (February 2026 wave); federal court filings in the outsourcing-association litigation; state boards of pharmacy for licensure specifics.
Clinical
Peer-reviewed primary publications of the pivotal programs — SURMOUNT-1 (NEJM 2022), SURMOUNT-2 (Lancet 2023), SURMOUNT-3/-4 (2023), SURMOUNT-5 (NEJM 2025), SURPASS-CVOT (2025), STEP 1 (NEJM 2021), STEP 5, the STEP 1 extension, SELECT (NEJM 2023), OASIS oral-semaglutide program, ATTAIN-1 (orforglipron, 2025), retatrutide phase 2 (NEJM 2023), REDEFINE-1 (CagriSema, 2025) — plus FDA labels for dosing, warnings, and contraindications. Trial numbers are attributed to the approved products studied, never to compounded copies.
Conflicts rule
When sources disagree, the provider's own current page beats everything for price; the FDA record beats everything for regulatory status; the primary publication beats every summary for clinical numbers — and unresolved conflicts are stated as conflicts, not averaged.